Metabolic evidence
Tirzepatide and heart failure: what SUMMIT’s combined outcome means
Read SUMMIT’s tirzepatide heart-failure results: the combined endpoint, separate death counts, health-status score and current US label context.
The SlimWithPeps reading room
Weight and metabolism
How to read research on GLP-1 medicines and emerging metabolic compounds.
23 articles · Newest first
Metabolic evidence
Semaglutide for MASH: why ESSENCE reported two biopsy answers
Understand ESSENCE’s two liver-biopsy endpoints, the 72-week interim findings and what Wegovy’s accelerated MASH approval does and does not establish.
Metabolic evidence
Semaglutide and heart risk: how to read SELECT’s 20% result
Understand SELECT’s 20% cardiovascular result, the absolute event proportions, the combined endpoint and who the semaglutide trial actually studied.
Metabolic evidence
GHRP-6 human research: why two half-lives do not make a treatment plan
Explore the small GHRP-6 human pharmacokinetic study, why distribution and elimination half-lives differ, and why neither establishes a treatment schedule.
Metabolic evidence
Weight regain after tirzepatide: the two starting points in SURMOUNT-4
Understand weight regain after tirzepatide, the two baselines in SURMOUNT-4, and why a percentage of body weight differs from a percentage of weight lost.
Metabolic evidence
Semaglutide vs liraglutide: reading the STEP 8 comparison
Understand the STEP 8 semaglutide–liraglutide comparison, percentage-point differences, treatment discontinuation and the limits of applying averages.
Metabolic evidence
Tirzepatide and lean mass: how to read the DXA results
Understand tirzepatide’s DXA findings, the difference between lean tissue and muscle, and why percentages of weight loss need careful interpretation.
Metabolic evidence
Tirzepatide and sleep apnea: what SURMOUNT-OSA actually measured
Understand SURMOUNT-OSA’s breathing-event results, the role of PAP in the trials, and what tirzepatide’s sleep-apnea approval does and does not mean.
Metabolic evidence
How oral semaglutide is absorbed: why the formulation matters
Explore how SNAC helps oral semaglutide absorption, what food-effect studies measured, and why tablet evidence cannot validate a different formulation.
Metabolic evidence
Semaglutide and kidney disease: what FLOW’s 24% reduction means
Read FLOW’s semaglutide kidney results, distinguish relative risk from percentage points, and see how new mechanism research fits the clinical evidence.
Metabolic evidence
Cagrilintide vs CagriSema: which treatment produced the result?
Cagrilintide and CagriSema are different interventions. Learn which trial produced each result, how analyses differ, and what FDA says about cagrilintide.
Metabolic evidence
Survodutide and MASH: improvement is not the same as fibrosis reversal
Read survodutide’s MASH trial accurately: why improvement without worsening fibrosis differs from scar reversal, and what its response rates measure.
Metabolic evidence
Weight regain after semaglutide: what two withdrawal studies tell us
What STEP 1 and STEP 4 found after semaglutide withdrawal, why their percentages differ, and what group averages cannot predict for an individual.
Metabolic evidence
GHRP-2 and appetite: what the human studies actually measured
What small human GHRP-2 studies found about appetite, what their meal-intake results cannot prove, and how FDA safety concerns change the context.
Metabolic evidence
Is MK-677 a peptide? Classification, human evidence and the muscle claim
MK-677 is not a peptide. Explore ibutamoren’s human trial evidence, why fat-free mass differs from strength, and its FDA status and safety concerns.
Metabolic evidence
AOD-9604 weight-loss evidence: why the larger trial matters
Explore AOD-9604 weight-loss research, the larger negative obesity trial, and why changes within a treatment group do not prove a treatment effect.
Metabolic evidence
Ipamorelin clinical trials: what the bowel-surgery study found
Read the human ipamorelin trial behind the claims: what researchers tested, the nonsignificant result, and why its safety findings need context.
Metabolic evidence
Sermorelin FDA status: the GEREF history explained
Understand the history of GEREF, its withdrawn approvals, and why an FDA finding about withdrawal does not approve a compounded sermorelin product.
Metabolic evidence
Compounded semaglutide: what the ingredient name does not tell you
Understand how compounded semaglutide differs from an approved medicine, why salt forms matter, and what to clarify with a prescriber or pharmacist.
Metabolic evidence
Tesamorelin: why its approved indication matters
Tesamorelin has a specific approved medical use. Learn why that differs from a general weight-loss claim and how to read the EGRIFTA WR label.
Metabolic evidence
CJC-1295 human studies: a hormone response is not a health outcome
Explore what early CJC-1295 trials measured, why increased GH and IGF-1 do not prove clinical benefit, and what safety questions remain.
Metabolic research
Retatrutide explained: what the trials can tell us
Understand the triple receptor agonist, its investigational status, and the questions to ask about new trial results.
Clinical studies
Tirzepatide vs semaglutide: reading the comparison fairly
What the SURMOUNT-5 trial found, which population it studied, and why averages are not individual predictions.